Dx Groups To FDA: Time For Companion Diagnostics Guidance Is Now
This article was originally published in The Gray Sheet
Executive Summary
Industry groups representing test manufacturers, labs, drug firms and others are redoubling their pressure on FDA to clarify the regulatory requirements for co-development of diagnostics and drug treatments